Home › Calculator › CYCN Dividend Calculator 2026
CYCN Dividend DRIP Calculator 2026
57.55% YieldHealthcareCyclerion Therapeutics, Inc. · NASDAQ
Price: $3.48 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When CYCN pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your CYCN snowball 📈
$10,000 in CYCN → $5636926978.26M in 10 years · $468,948,214,149,936.50/month
About Cyclerion Therapeutics, Inc. (CYCN) — Dividend Analysis 2026
Cyclerion Therapeutics, Inc. operates as a biopharmaceutical company in the clinical development phase, concentrating on the discovery, advancement, and commercialization of therapeutic agents for debilitating central nervous system (CNS) disorders. Their leading experimental compound, CY6463, is a soluble guanylate cyclase (sGC) stimulator designed to cross the blood-brain barrier. It is presently in Phase IIa clinical assessments for managing mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), as well as Alzheimer's disease with vascular involvement. Concurrently, CY6463 is undergoing Phase 1 trials for treating schizophrenia in adult populations. The company's research portfolio also features other promising candidates: Praliciguat, an orally administered systemic sGC stimulator, is in Phase II studies targeting resistant hypertension and diabetic nephropathy. Olinciguat, another sGC stimulator designed for oral intake with a vascular focus, is progressing through Phase II trials for sickle cell disease. Moreover, CY3018 is under development to address a range of CNS ailments. Cyclerion holds a licensing agreement with Akebia Therapeutics, Inc., covering the entire lifecycle from development and manufacturing to medical affairs and commercialization for certain pharmaceutical compounds and related products. The company was founded in 2018 and has its principal place of business in Cambridge, Massachusetts.
Compare CYCN with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full CYCN DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open CYCN position with:
🌍 CYCN Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold CYCN.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 57.55% | 54.75% | $5,755 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 48.92% | 46.12% | $4,892 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 46.04% | 43.24% | $4,604 / yr |
| 🇬🇧 UK ISA | 0% | 57.55% | 54.75% | $5,755 / yr |
| 🇬🇧 UK Taxable | 8.75% | 52.51% | 49.71% | $5,251 / yr |
| 🇨🇦 TFSA | 0% | 57.55% | 54.75% | $5,755 / yr |
| 🇨🇦 CA Taxable | 25% | 43.16% | 40.36% | $4,316 / yr |
| 🇦🇺 Super (pension) | 15% | 48.92% | 46.12% | $4,892 / yr |
| 🇦🇺 AU Taxable | 30% | 40.28% | 37.48% | $4,029 / yr |
| 🇩🇪 DE Taxable | 26.375% | 42.37% | 39.57% | $4,237 / yr |
| 🇫🇷 FR Taxable | 30% | 40.28% | 37.48% | $4,029 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 CYCN Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 CYCN Dividend Payment Schedule
CYCN pays quarterly — 4 times per year. Next ex-div: TBD.
📊 CYCN vs Healthcare Benchmarks
How CYCN compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for CYCN sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ CYCN Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| C-Conversion | 2026-07-16 | 351,037 | $8.68 | $3.05M | ||
| C-Conversion | 2026-07-16 | 351,037 | — | — | ||
| A-Award | 2025-08-07 | 25,000 | $2.35 | $58.9K | ||
| A-Award | 2025-03-25 | 181,818 | $2.75 | $500.0K | ||
| A-Award | 2025-03-25 | 9,090 | $2.75 | $25.0K | ||
| Sale | 2024-11-21 | 357,880 | $1.55 | $555.1K | ||
| A-Award | 2024-08-05 | 55,849 | $3.30 | $184.3K | ||
| A-Award | 2024-01-01 | 15,000 | — | — | ||
| A-Award | 2024-01-01 | 50,000 | — | — | ||
| A-Award | 2023-11-30 | 5,000 | — | — |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the CYCN dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Cyclerion Therapeutics, Inc. (CYCN) is currently trading at $3.48, 96% below its 52-week high. The current dividend yield is 57.55% based on an annual payout of $2.00 per share.
CYCN (Cyclerion Therapeutics, Inc.) — 57.55% Dividend Yield Analysis
Cyclerion Therapeutics, Inc. (CYCN) is a healthcare stock currently trading at $3.48 with a dividend yield of 57.55%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (57.55%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.